Literature DB >> 10975239

Liquid chromatographic determination of urinary 6beta-hydroxycortisol to assess cytochrome p-450 3A activity in HIV positive pregnant women.

M Homma1, K Beckerman, S Hayashi, A L Jayewardene, K Oka, J G Gambertoglio, F T Aweeka.   

Abstract

Assessing the activity of CYP3A4 is important for predicting the pharmacokinetic behavior of protease inhibitors in HIV positive patients, especially in pregnant women. The endogenous hormonal ratio of 6beta-hydroxycortisol (beta-OHF) to cortisol (F) in the urine is an index for metabolic enzyme activity of cytochrome p-450 (CYP) 3A4. Because the ratio is a unique way to assess the enzyme activity without using any exogenous probes for this isozyme, it is practical for use in pregnant women. In this paper, we describe a method using high performance liquid chromatography (HPLC) for 6beta-OHF in urine from pregnant women to estimate the ratio of 6beta-OHF/F. Urinary 6beta-OHF was measured by using C18-cartridge solid phase extraction and isocratic HPLC. Aliquots (1 ml) of urine samples spiked with internal standard, 6beta-hydroxyprednisolone (6beta-OHPSL), were alkalinized with NaOH, then applied to C18-cartridges, which were washed with water and hexane and eluted with ethyl acetate. After the effluents were dried and reconstituted in 10% acetonitrile, the samples were analyzed by HPLC using an isocratic mobile phase (acetic acid/acetonitrile/50 mM potassium dihydrogenphosphate: 0.2/9/90.8; v/v) and ultraviolet detection at 245 nm. The recoveries of 6beta-OHF from C18 cartridges were 93.2 and 93.9% when the authentic 6beta-OHF was added to the urine sample at the concentration of 50 and 300 ng/ml, respectively. Intra- and inter-day variations estimated at concentrations of 113-674 ng/ml were 2.9-5.6 and 4.9-8.1%, respectively. The method was applied to morning urine samples collected from HIV-positive pregnant women managed with protease inhibitor containing anti-retroviral regimens.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10975239     DOI: 10.1016/s0731-7085(00)00334-4

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  6 in total

1.  Modification of CYP2E1 and CYP3A4 activities in haemoglobin E-beta thalassemia patients.

Authors:  Nuntiya Somparn; Upa Kukongviriyapan; Wichittra Tassaneeyakul; Arunee Jetsrisuparb; Veerapol Kukongviriyapan
Journal:  Eur J Clin Pharmacol       Date:  2006-11-21       Impact factor: 2.953

Review 2.  Evolution and function of the NR1I nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xenobiotics and endogenous compounds.

Authors:  E J Reschly; Matthew D Krasowski
Journal:  Curr Drug Metab       Date:  2006-05       Impact factor: 3.731

3.  Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients.

Authors:  Jacques Fellay; Catia Marzolini; Laurent Decosterd; Kerry Powell Golay; Pierre Baumann; Thierry Buclin; Amalio Telenti; Chin B Eap
Journal:  Eur J Clin Pharmacol       Date:  2005-01-19       Impact factor: 2.953

4.  Protein binding of lopinavir and ritonavir during 4 phases of pregnancy: implications for treatment guidelines.

Authors:  Kristine B Patterson; Julie B Dumond; Heather A Prince; Amanda J Jenkins; Kimberly K Scarsi; Ruili Wang; Stephanie Malone; Michael G Hudgens; Angela D M Kashuba
Journal:  J Acquir Immune Defic Syndr       Date:  2013-05-01       Impact factor: 3.731

5.  Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure.

Authors:  David W Ouyang; David E Shapiro; Ming Lu; Susan B Brogly; Audrey L French; Robert M Leighty; Bruce Thompson; Ruth E Tuomala; Ronald C Hershow
Journal:  AIDS       Date:  2009-11-27       Impact factor: 4.177

Review 6.  Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.

Authors:  M M Galteau; F Shamsa
Journal:  Eur J Clin Pharmacol       Date:  2003-11-06       Impact factor: 2.953

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.